November 3, 2025, should have registered as a turning point for Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0). Yet, the date passed with little market fanfare, even though it marked the release of top-line results from the company’s GUARDIAN study, data that promises to reshape the treatment landscape for Duchenne muscular dystrophy.
Duchenne, a rare and devastating muscle-wasting disease, affects boys and young men exclusively. It is progressive, life-shortening and relentless. For decades, care has relied on a blunt instrument: corticosteroids. They work, after a fashion.
They slow muscle deterioration, extend walking by a few years and delay cardiac and respiratory failure. They also exact a heavy toll, reshaping bodies and lives through weight gain, brittle bones, stunted growth, fractures, cataracts and mood disorders. Families have long understood the trade-off. Physicians have had little choice but to accept it.
Real benefits
The GUARDIAN read-out suggested that this grim arithmetic may finally be changing. Santhera’s drug, AGAMREE, delivered the functional benefits of traditional corticosteroids with significantly fewer and less severe side effects. Researchers had suspected as much. One-year data already pointed in that direction. What GUARDIAN added was time. Up to eight years' data, with the median follow-up being around five years.
For parents weighing impossible decisions, and for clinicians conditioned to distrust early promise, that span matters. It answers the question that shadows every new therapy: not just whether it works, but whether it keeps working. Whether efficacy endures. Whether the safety profile holds when the calendar turns.
To understand why this matters, it helps to step back. Corticosteroids entered use in the late 1940s. They remain, nearly 80 years on, the standard of care for Duchenne. No adequate replacement emerged, despite decades of research and incremental innovation. By modern standards, the approach is crude, even brutal. Yet for want of alternatives, it persisted.
Changing the equation
AGAMREE was engineered to change that equation. Proof of concept was never the issue. Persuasion was. Medicine, particularly in rare diseases, is conservative for good reason. Protocols harden. Evidence accumulates slowly. But what the GUARDIAN study supplied was longitudinal reassurance that changes behaviour.
The shift is already visible. In Austria, AGAMREE has captured roughly half the market. In Germany, about 40%. For a first full year on sale, those figures are striking.
“It is worth remembering that 2025 was the first full year for the product. For any launch, reaching those levels in a first full year is an excellent result,” says Santhera chief financial officer Catherine Isted.
“A key driver of future market share growth will be the GUARDIAN study. One of the main challenges we faced was that our original data covered a relatively short period, up to one year.
“Prescribing doctors told us that one-year results are helpful, but what really matters is whether the same level of effectiveness is maintained over a longer period, and whether the safety profile continues to hold up over time. They wanted to know if the benefits were lasting or simply short-term markers."
Important data
“That is why the data we released in November is so important. It covers five years, extending in some cases to eight years. We have shown that our treatment matches standard corticosteroids in terms of effectiveness, while offering clear and significant advantages on safety," Isted added.
The commercial implications follow from the clinical ones. Duchenne is rare. Roughly 300,000 boys and young men worldwide live with the condition. This is not a mass-market drug, nor will it ever be. But rarity cuts both ways. It limits competition. It discourages pharmaceutical giants from flooding the field with near-identical alternatives. In such spaces, durable franchises can form.
Santhera’s strategy reflects that reality. In Europe, the company sells directly, building its own relationships with physicians. Germany, Austria and the UK are already live, with wider European launches underway during 2026.
Elsewhere, scale matters more. In the US, China and Japan, Santhera has partnered with larger pharmaceutical groups that bring reach, capital and infrastructure. The trade-off is shared economics: upfront payments, milestones and royalties rather than full ownership. Most major markets are now covered, with Latin America expected to follow.
European anchor
Europe remains the financial anchor, with management targeting €150 million in annual revenue by 2030 from those direct markets. The assumptions behind that figure are deliberately cautious.
Currently, Santhera is targeting uptake from 5,000 patients and a price of around €2,000 per bottle, based on 15 bottles per patient per year.
Those assumptions may prove conservative. In Germany, AGAMREE sells for about €3,000 a bottle, suggesting a European average closer to €2,500 may be more realistic.
Market penetration could also exceed current expectations. Around 8,000 boys and young men take corticosteroids today, but an additional 3,000 to 5,000 do not receive standard treatment because of side effects. Wider awareness of AGAMREE could bring some of those patients into therapy.
Break-even in sight
The company expects to reach cash flow break-even by around mid-year, with revenues building more meaningfully as additional European countries come online.
“Investors should focus on how we are performing in Germany and Austria, as well as on the pace of launches and pricing,” CFO Isted says.
“By the middle of the year, we expect to have several more European countries on stream, and that is when sales should begin to build more meaningfully.
“In most of those markets, the first full year of revenue will be 2027, with a partial contribution in 2026. That is the right way to think about the cost base, and about how revenues and cash flows will start to come through to us over the next few years.”
Early signals from the US are also encouraging. Santhera’s partner Catalyst is understood to have generated in excess of $115 million in AGAMREE sales in 2025, evidence that adoption is not confined to Europe. Catalyst is also exploring uses beyond Duchenne, positioning the drug as a potential replacement for traditional corticosteroids in other conditions, a move that could materially expand the opportunity set, while bringing further double-digit royalties to Santhera, in addition to speeding up time to achieving various sales milestones.
Bolt-on deals?
AGAMREE, meanwhile, is not meant to stand alone. Santhera is actively looking at bolt-on acquisitions that could be layered onto its existing sales platform, squeezing more value from infrastructure already in place.
Analysts have taken note. Swiss brokerage Octavian estimates revenues rising from an estimated CHF 71.6 million to CHF 120.6 million this year, with EBITDA approaching CHF 50 million in 2026. It sees peak sales of CHF 525 million across Europe and partner-led markets, underpinning a price target well above current levels.
The usual caveats apply at this point. This analysis reflects management guidance and publicly available information.
Drug launches are rarely without setbacks, though execution so far has been strong.
Striking disconnect
The bigger uncertainty is political. Tariffs, pricing reform and the Trump administration’s Most Favoured Nation initiative introduce volatility, even if rare diseases such as DMD are ultimately exempted.
Still, the disconnect is striking. Here is a company with long-term clinical data, visible changes in prescribing behaviour and a commercial strategy that appears to be working. And yet, it remains easy to overlook.
That leaves a single, pressing question: how long can a company delivering clinical and commercial progress at this pace continue to pass largely unnoticed by the market?